covid19.healthdata.org 1 Institute for Health Metrics and Evaluation
Informe de resultados de COVID-19
México
23 de junio de 2021 Este documento contiene información resumida sobre las últimas proyecciones del modelo IHME sobre COVID-19 en México. El modelo se ejecutó el 23 de junio de 2021 con datos hasta el 21 de junio de 2021.
Situación actual • Los casos notificados diariamente en la última semana aumentaron a 2,600 por día en promedio en comparación con los 2,200 de la semana anterior (Figura 1).
• Las muertes diarias en la última semana disminuyeron a 150 por día en promedio en comparación con 160 la semana anterior (Figura 2). Las muertes diarias totales estimadas por COVID-19 fueron 2.3 veces mayores que la cantidad informada de muertes. Esto convierte al COVID-19 en la cuarta causa de muerte en México esta semana (Tabla 1).
• La tasa de mortalidad diaria es superior a 4 por millón en Campeche, Quintana Roo, Tamaulipas y Yucatán (Figura 3).
• Estimamos que 53% de las personas en México han sido infectadas al 21 de junio. En 18 estados más de la mitad de la población está infectada (Figura 5).
• La R efectiva, calculada usando casos, hospitalizaciones y muertes, es mayor que 1 en 14 estados (Figura 6).
• La tasa de detección de infecciones en México fue cercana a 5% el 21 de junio (Figura 7).
• Con base en el GISAID y varias bases de datos nacionales, combinado con nuestro modelo de dispersión de variantes, estimamos la prevalencia actual de variantes de interés (Figura 8). Estimamos que las variantes circulantes primarias son variantes ancestrales y B.1.1.7. Estimamos que B.1.351 está circulando en 0 estados, que B.1.617 está circulando en 25 estados y que P.1 o P.3 está circulando en 26 estados.
Tendencias en los impulsores de la transmisión • La movilidad la semana pasada fue un 3% más baja que la línea de base anterior a COVID-19 (Figura 10). La movilidad estuvo cerca de la línea de base (dentro del 10%) en 29 estados. La movilidad fue inferior al 30% de la línea de base en ningún lugar.
• Al 21 de junio, en las encuestas globales de síntomas COVID-19 y las encuestas de síntomas COVID-19 de EE. UU., el 79% de las personas informan que siempre usaban una máscara al salir de casa, sin cambios en comparación con la semana pasada (Figura 12). En ningún estado el uso de mascarillas fue inferior a 50%.
• Se realizaron 10 pruebas de diagnóstico por cada 100,000 personas el 21 de junio (Figura 14).
covid19.healthdata.org 2 Institute for Health Metrics and Evaluation
• En México, el 89.4% de las personas dicen que aceptarían o probablemente aceptarían una vacuna para COVID-19. Esto es 0 puntos porcentuales más que la semana pasada. La fracción de la población que está dispuesta a recibir la vacuna COVID-19 oscila entre 83% en Quintana Roo y 94% en el estado de México (Figura 18).
• En nuestro escenario de referencia actual, esperamos que 59.9 millones de personas estén vacunadas para el 1 de octubre (Figura 19).
Proyecciones • En nuestro escenario de referencia, que representa lo que creemos que es más probable que suceda, nuestro modelo proyecta 588,000 muertes acumuladas el 1 de octubre. Esto representa 41,000 muertes adicionales del 21 de junio al 1 de octubre (Figura 20). Las muertes diarias alcanzarán un máximo de 640 el 1 de octubre de 2021 (Figura 21).
• Si se alcanzara la cobertura universal de la mascarilla (95%) en la próxima semana, nuestro modelo proyecta 11,000 muertes acumulativas menos en comparación con el escenario de referencia del 1 de octubre (Figura 20).
• En nuestro peor escenario, nuestro modelo proyecta 616,000 muertes acumuladas el 1 de octubre, 28,000 muertes adicionales en comparación con nuestro escenario de referencia (Figura 20). Se espera que las muertes diarias en el peor escenario disminuyan de manera constante hasta el 1 de octubre de 2021 (Figura 21).
• Para el 1 de octubre, proyectamos que se salvarán 20,900 vidas gracias a la vacunación. Esto no incluye las vidas salvadas mediante la vacunación que ya se ha entregado.
• Se espera que las infecciones diarias en el escenario de referencia disminuyan de manera constante hasta el 1 de octubre de 2021. En el peor escenario, se espera que las infecciones diarias disminuyan de manera constante hasta el 1 de octubre de 2021 (Figura 22).
• La Figura 23 compara nuestros pronósticos de escenarios de referencia con otros modelos archivados públicamente. Las proyecciones son muy divergentes. IHME proyecta un incremento de las muertes diarias, mientras que los demás modelos proyectan una paulatina disminución.
• En algún momento, desde junio hasta el 1 de octubre, 17 estados tendrán una presión alta o extrema en las camas de hospital (Figura 24). En algún momento, desde junio hasta el 1 de octubre, 23 estados tendrán una presión alta o extrema en la capacidad de la UCI (Figura 25).
covid19.healthdata.org 3 Institute for Health Metrics and Evaluation
COVID-19 Results Briefing
Mexico
June 23, 2021 This document contains summary information on the latest projections from the IHME model on COVID-19 in Mexico. The model was run on June 23, 2021, with data through June 21, 2021.
Current situation • Daily reported cases in the last week increased to 2,600 per day on average compared
to 2,200 the week before (Figure 1).
• Daily deaths in the last week decreased to 150 per day on average compared to 160 the week before (Figure 2). Estimated total daily COVID-19 deaths were 2.3 times larger than the reported number of deaths. This makes COVID-19 the number 4 cause of death in Mexico this week (Table 1).
• The daily death rate is greater than 4 per million in Campeche, Quintana Roo, Tamaulipas, and Yucatán (Figure 3).
• We estimated that 53% of people in Mexico have been infected as of June 21. In 18 states, more than half the population are infected (Figure 5).
• Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in 14 states (Figure 6).
• The infection-detection rate in Mexico was close to 5% on June 21 (Figure 7).
• Based on the GISAID and various national databases, combined with our variant spread model, we estimate the current prevalence of variants of concern (Figure 8). We estimate that the primary circulating variants are ancestral and B.1.1.7 variants. We estimate that B.1.351 is not circulating in any states, that B.1.617 is circulating in 25 states, and that P.1 or P.3 is circulating in 26 states.
Trends in drivers of transmission • Mobility last week was 3% lower than the pre-COVID-19 baseline (Figure 10). Mobility
was near baseline (within 10%) in 29 states. Mobility was not lower than 30% of baseline in any locations.
• As of June 21, in the Global COVID-19 Symptom Surveys and the US COVID-19 Symptom Surveys, 79% of people self-report that they always wore a mask when leaving their home, about the same as last week (Figure 12). Mask use was not lower than 50% in any states.
• There were 10 diagnostic tests per 100,000 people on June 21 (Figure 14).
covid19.healthdata.org 4 Institute for Health Metrics and Evaluation
• In Mexico, 89.4% of people say they would accept or would probably accept a vaccine for COVID-19. This is about the same percentage as last week. The fraction of the population who are open to receiving a COVID-19 vaccine ranges from 83% in Quintana Roo to 94% in México (Figure 18).
• In our current reference scenario, we expect that 59.9 million people will be vaccinated by October 1 (Figure 19).
Projections • In our reference scenario, which represents what we think is most likely to happen,
our model projects 588,000 cumulative deaths on October 1. This represents 41,000 additional deaths from June 21 to October 1 (Figure 20). Daily deaths will peak at 640 on October 1, 2021 (Figure 21).
• If universal mask coverage (95%) were attained in the next week, our model projects 11,000 fewer cumulative deaths compared to the reference scenario on October 1 (Figure 20).
• Under our worse scenario, our model projects 616,000 cumulative deaths on October 1, an additional 28,000 deaths compared to our reference scenario (Figure 20). Daily deaths in the worse scenario are expected to decline steadily until October 1, 2021 (Figure 21).
• By October 1, we project that 20,900 lives will be saved by the projected vaccine rollout. This does not include lives saved through vaccination that has already been delivered.
• Daily infections in the reference scenario are expected to decline steadily until October 1, 2021. Under the worse scenario, daily infections are expected to decline steadily until October 1, 2021 (Figure 22).
• Figure 23 compares our reference scenario forecasts to other publicly archived models. Forecasts are widely divergent. IHME projects an increase in daily deaths, while the other models project a gradual decrease.
• At some point from June through October 1, 17 states will have high or extreme stress on hospital beds (Figure 24). At some point from June through October 1, 23 states will have high or extreme stress on ICU capacity (Figure 25).
Mexico COVID-19 RESULTS BRIEFING
Model updatesFollowing on our update last week to model all variant data simultaneously, we augmented our variant spreadalgorithms to model spread of all variants simultaneously across all locations at once. We have observedsimultaneous or near-simultaneous invasion across many locations, and this new approach allows us to moreclosely capture the data. As before, locations with a variant may spread it to their neighbors or locationsconnected through large flows (based on a gravity model), but now we have also instituted a hierarchyof variants based on observations of variant-variant interaction. In particular, if B.1.617.2 is already thedominant variant, no other variant is allowed to invade on top of it. From B.1.617.2, the hierarchy is P.1,B.1.617.1, B.1.1.7, and B.1.351. In each case, a variant may not invade if all the current infections in alocation are estimated to be of a variant above it in the hierarchy.
Our previous assessment of the total COVID-19 to reported COVID-19 death scalar for Georgia was 3.73.This was based on the estimated infection-detection rate (IDR) for Georgia and information on the scalarsfrom other countries in the GBD region and super-region. We opted to use such estimates for the countrybecause the reported all-cause mortality data, which are needed to estimate excess mortality as described inour online method description, were only available up to the 26th week of 2020, before the epidemic becamesevere. We have since received all-cause mortality data from our collaborators in Georgia up to week 13of 2021. This has allowed us to directly estimate the scalar after accounting for the impact of flu, or lackthereof, in the first three months of 2021. Our new scalar is 2.04 for Georgia, which reflects such changes.
covid19.healthdata.org 3 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 1. Reported daily COVID-19 cases
0
5,000
10,000
15,000
Feb 20 Apr 20 Jun 20 Aug 20 Oct 20 Dec 20 Feb 21 Apr 21 Jun 21Month
Cou
nt
Daily cases
Table 1. Ranking of COVID-19 among the leading causes of mortality this week, assuming uniform deathsof non-COVID causes throughout the year
Cause name Weekly deaths RankingIschemic heart disease 2,044 1Diabetes mellitus 1,420 2Chronic kidney disease 1,395 3COVID-19 1,080 4Cirrhosis and other chronic liver diseases 891 5Stroke 729 6Chronic obstructive pulmonary disease 630 7Interpersonal violence 590 8Alzheimer’s disease and other dementias 455 9Lower respiratory infections 434 10
covid19.healthdata.org 4 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 2. Smoothed trend estimate of reported daily COVID-19 deaths (blue) and total daily COVID-19deaths (orange).
0
1,000
2,000
3,000
Jan 20 Mar 20 May 20 Jul 20 Sep 20 Nov 20 Jan 21 Mar 21 May 21 Jul 21
Dai
ly d
eath
s
covid19.healthdata.org 5 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 3. Daily COVID-19 death rate per 1 million on June 21, 2021
<1
1 to 1.9
2 to 2.9
3 to 3.9
4 to 4.9
5 to 5.9
6 to 6.9
7 to 7.9
>=8
Figure 4. Cumulative COVID-19 deaths per 100,000 on June 21, 2021
<50
50 to 99
100 to 149
150 to 199
200 to 249
250 to 299
300 to 349
350 to 399
>=400
covid19.healthdata.org 6 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 5. Estimated percent of the population infected with COVID-19 on June 21, 2021
<10
10−19.9
20−29.9
30−39.9
40−49.9
50−59.9
60−69.9
70−79.9
80−84.9
85−89.9
90−94.9
>=95
Figure 6. Mean effective R on June 10, 2021. The estimate of effective R is based on the combined analysisof deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11-13days prior, so estimates of effective R can only be made for the recent past. Effective R less than 1 meansthat transmission should decline, all other things being held the same.
<0.79
0.79−0.84
0.85−0.89
0.9−0.94
0.95−0.99
1−1.04
1.05−1.09
1.1−1.14
1.15−1.2
>=1.21
covid19.healthdata.org 7 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 7. Percent of COVID-19 infections detected. This is estimated as the ratio of reported dailyCOVID-19 cases to estimated daily COVID-19 infections based on the SEIR disease transmission model. Dueto measurement errors in cases and testing rates, the infection-detection rate can exceed 100% at particularpoints in time.
0%
25%
50%
75%
100%
May 20 Jul 20 Sep 20 Nov 20 Jan 21 Mar 21 May 21 Jul 21
Per
cent
of i
nfec
tions
det
ecte
d
Argentina United States of America Colombia Mexico Brazil
covid19.healthdata.org 8 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 8. Estimated percent of circulating SARS-CoV-2 for primary variant families on June 21, 2021.
A. Estimated percent B.1.1.7 variant
0%
1−9%
10−24%
25−49%
50−74%
75−89%
90−100%
B. Estimated percent B.1.351 variant
0%
1−9%
10−24%
25−49%
50−74%
75−89%
90−100%
covid19.healthdata.org 9 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
C. Estimated percent B.1.617 variant
0%
1−9%
10−24%
25−49%
50−74%
75−89%
90−100%
D. Estimated percent P.1 variant
0%
1−9%
10−24%
25−49%
50−74%
75−89%
90−100%
covid19.healthdata.org 10 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 9. Infection-fatality ratio on June 21, 2021
< 0.2%
0.2% to 0.39%
0.4% to 0.59%
0.6% to 0.79%
0.8% to 0.99%
> 1%
covid19.healthdata.org 11 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Critical driversTable 2. Current mandate implementation
Prim
ary
scho
ol c
losu
reS
econ
dary
sch
ool c
losu
reH
ighe
r sc
hool
clo
sure
Bor
ders
clo
sed
to a
ny n
on−
resi
dent
Bor
ders
clo
sed
to a
ll no
n−re
side
nts
Indi
vidu
al m
ovem
ents
res
tric
ted
Cur
few
for
busi
ness
esIn
divi
dual
cur
few
Gat
herin
g lim
it: 6
indo
or, 1
0 ou
tdoo
rG
athe
ring
limit:
10
indo
or, 2
5 ou
tdoo
rG
athe
ring
limit:
25
indo
or, 5
0 ou
tdoo
rG
athe
ring
limit:
50
indo
or, 1
00 o
utdo
orG
athe
ring
limit:
100
indo
or, 2
50 o
utdo
orR
esta
uran
ts c
lose
dB
ars
clos
edR
esta
uran
ts /
bars
clo
sed
Res
taur
ants
/ ba
rs c
urbs
ide
only
Gym
s, p
ools
, oth
er le
isur
e cl
osed
Non
−es
sent
ial r
etai
l clo
sed
Non
−es
sent
ial r
etai
l cur
bsid
e on
lyN
on−
esse
ntia
l wor
kpla
ces
clos
edS
tay
hom
e or
der
Sta
y ho
me
fine
Mas
k m
anda
teM
ask
man
date
fine
ZacatecasYucatán
Veracruz de Ignacio de la LlaveTlaxcala
TamaulipasTabascoSonoraSinaloa
San Luis PotosíQuintana Roo
QuerétaroPuebla
OaxacaNuevo León
NayaritMéxico
MorelosMichoacán de Ocampo
Mexico CityJalisco
HidalgoGuerrero
GuanajuatoDurango
ColimaCoahuila
ChihuahuaChiapas
CampecheBaja California Sur
Baja CaliforniaAguascalientes
Mandate in placeMandate in place(imposed this week)Mandate in place(updated from previous reporting)
No mandateNo mandate(lifted this week)No mandate(updated from previous reporting)
covid19.healthdata.org 12 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 10. Trend in mobility as measured through smartphone app use compared to January 2020 baseline
−80
−60
−40
−20
0
Jan 20 Mar 20 May 20 Jul 20 Sep 20 Nov 20 Jan 21 Mar 21 May 21 Jul 21
Per
cent
red
uctio
n fr
om a
vera
ge m
obili
ty
Argentina United States of America Colombia Mexico Brazil
Figure 11. Mobility level as measured through smartphone app use compared to January 2020 baseline(percent) on June 21, 2021
=<−50
−49 to −45
−44 to −40
−39 to −35
−34 to −30
−29 to −25
−24 to −20
−19 to −15
−14 to −10
>−10
covid19.healthdata.org 13 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 12. Trend in the proportion of the population reporting always wearing a mask when leaving home
0
25
50
75
Mar 20 May 20 Jul 20 Sep 20 Nov 20 Jan 21 Mar 21 May 21 Jul 21
Per
cent
of p
opul
atio
n
Argentina United States of America Colombia Mexico Brazil
Figure 13. Proportion of the population reporting always wearing a mask when leaving home on June 21,2021
<45%
45 to 49%
50 to 54%
55 to 59%
60 to 64%
65 to 69%
70 to 74%
75 to 79%
80 to 84%
>=85%
covid19.healthdata.org 14 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 14. Trend in COVID-19 diagnostic tests per 100,000 people
0
200
400
Jan 20 Mar 20 May 20 Jul 20 Sep 20 Nov 20 Jan 21 Mar 21 May 21 Jul 21
Test
per
100
,000
pop
ulat
ion
Argentina United States of America Colombia Mexico Brazil
Figure 15. COVID-19 diagnostic tests per 100,000 people on June 21, 2021
<5
5 to 9.9
10 to 24.9
25 to 49
50 to 149
150 to 249
250 to 349
350 to 449
450 to 499
>=500
covid19.healthdata.org 15 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 16. Increase in the risk of death due to pneumonia on February 1 compared to August 1
<−60%
−60 to −41%
−40 to −21%
−20 to −1%
0 to 19%
20 to 39%
40 to 59%
>=60%
covid19.healthdata.org 16 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Table 3. Estimates of vaccine efficacy for specific vaccines used in the model at preventing disease andinfection. The SEIR model uses variant-specific estimates of vaccine efficacy at preventing symptomaticdisease and at preventing infection. We use data from clinical trials directly, where available, and makeestimates otherwise. More information can be found on our website.
Vaccine
Efficacy atpreventing disease:D614G & B.1.1.7
Efficacy atpreventing
infection: D614G &B.1.1.7
Efficacy at preventingdisease: B.1.351,B.1.617, & P.1
Efficacy at preventinginfection: B.1.351,B.1.617, & P.1
AstraZeneca 74% 52% 35% 31%CoronaVac 50% 44% 32% 28%Covaxin 78% 69% 50% 44%Janssen 72% 72% 64% 57%Moderna 94% 89% 89% 85%Novavax 89% 79% 49% 43%Pfizer/BioNTech 91% 86% 86% 82%Sinopharm 73% 65% 47% 41%Sputnik-V 92% 81% 59% 52%TianjinCanSino
66% 58% 42% 37%
Othervaccines
75% 66% 57% 50%
Othervaccines(mRNA)
91% 86% 86% 82%
covid19.healthdata.org 17 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 17. Trend in the estimated proportion of the adult (18+) population that have been vaccinated orwould probably or definitely receive the COVID-19 vaccine if available.
0
25
50
75
100
Jan 21 Feb 21 Mar 21 Apr 21 May 21 Jun 21
Per
cent
of p
opul
atio
n
Argentina United States of America Colombia Mexico Brazil
Figure 18. This figure shows the estimated proportion of the adult (18+) population that has been vaccinatedor would probably or definitely receive the COVID-19 vaccine if available.
<50%
50−59%
60−69%
70−74%
75−79%
80−84%
>85%
covid19.healthdata.org 18 Institute for Health Metrics and Evaluation
Mexico COVID-19 RESULTS BRIEFING
Figure 19. Number of people who receive any vaccine and those who are effectively vaccinated and protectedagainst disease, accounting for efficacy, loss to follow up for two-dose vaccines, partial immunity after onedose, and immunity after two doses.
0
20,000,000
40,000,000
60,000,000
0
20
40
60
Dec 2
0
Jan
21
Feb
21
Mar
21
Apr 2
1
May
21
Jun
21
Jul 2
1
Aug 2
1
Sep 2
1
Oct 21
Peo
ple
Percent of adult population
At least one dose Effectively vaccinated
covid19.healthdata.org 19 Institute for Health Metrics and Evaluation
Mexico PROJECTIONS AND SCENARIOS
Projections and scenariosWe produce three scenarios when projecting COVID-19. The reference scenario is our forecast of what wethink is most likely to happen:
• Vaccines are distributed at the expected pace.• Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever
daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 dayswith daily deaths above this rate and not yet re-imposed social distancing mandates. In this case, thescenario assumes that mandates are re-imposed when daily deaths reach 15 per million.
• Variants B.1.1.7 (first identified in the UK), B.1.351 (first identified in South Africa), and P1 (firstidentified in Brazil) continue to spread from locations with (a) more than 5 sequenced variants, and(b) reports of community transmission, to adjacent locations following the speed of variant scale-upobserved in the regions of the United Kingdom.
• In one-quarter of those vaccinated, mobility increases toward pre-COVID-19 levels.
The worse scenario modifies the reference scenario assumptions in three ways:
• First, it assumes that variants B.1.351 or P.1 begin to spread within three weeks in adjacent locationsthat do not already have B.1.351 or P.1 community transmission.
• Second, it assumes that all those vaccinated increase their mobility toward pre-COVID-19 levels.• Third, it assumes that among those vaccinated, mask use starts to decline exponentially one month
after completed vaccination.
The universal masks scenario makes all the same assumptions as the reference scenario but also assumes95% of the population wear masks in public in every location.
covid19.healthdata.org 20 Institute for Health Metrics and Evaluation
Mexico PROJECTIONS AND SCENARIOS
Figure 20. Cumulative COVID-19 deaths until October 01, 2021 for three scenarios
0
200,000
400,000
600,000
0
100
200
300
400
500
Oct 20 Nov 20 Dec 20 Jan 21 Feb 21 Mar 21 Apr 21 May 21 Jun 21 Jul 21 Aug 21 Sep 21 Oct 21
Cum
ulat
ive
deat
hsC
umulative deaths per 100,000
Reference scenario
Universal mask use
Worse
Figure 21. Daily COVID-19 deaths until October 01, 2021 for three scenarios
0
1,000
2,000
3,000
0
1
2
Jan 20 Mar 20 May 20 Jul 20 Sep 20 Nov 20 Jan 21 Mar 21 May 21 Jul 21 Sep 21 Nov 21
Dai
ly d
eath
sD
aily deaths per 100,000
Reference scenario
Universal mask use
Worse
covid19.healthdata.org 21 Institute for Health Metrics and Evaluation
Mexico PROJECTIONS AND SCENARIOS
Figure 22. Daily COVID-19 infections until October 01, 2021 for three scenarios
0
100,000
200,000
300,000
0
50
100
150
200
250
Jan 20 Mar 20 May 20 Jul 20 Sep 20 Nov 20 Jan 21 Mar 21 May 21 Jul 21 Sep 21 Nov 21
Dai
ly in
fect
ions
Daily infections per 100,000
Reference scenario
Universal mask use
Worse
covid19.healthdata.org 22 Institute for Health Metrics and Evaluation
Mexico PROJECTIONS AND SCENARIOS
Figure 23. Comparison of reference model projections with other COVID modeling groups. For thiscomparison, we are including projections of daily COVID-19 deaths from other modeling groups when available:Delphi from the Massachusetts Institute of Technology (Delphi), Imperial College London (Imperial), The LosAlamos National Laboratory (LANL), and the SI-KJalpha model from the University of Southern California(SIKJalpha). Daily deaths from other modeling groups are smoothed to remove inconsistencies with rounding.Regional values are aggregates from available locations in that region.
200
400
600
Jul 21 Aug 21 Sep 21 Oct 21Date
Dai
ly d
eath
s
Models
IHME
Imperial
LANL
SIKJalpha
covid19.healthdata.org 23 Institute for Health Metrics and Evaluation
Mexico PROJECTIONS AND SCENARIOS
Figure 24. The estimated inpatient hospital usage is shown over time. The percent of hospital beds occupiedby COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of beds occupiedby COVID-19 patients. Less than 5% is considered low stress, 5-9% is considered moderate stress, 10-19% isconsidered high stress, and 20% or greater is considered extreme stress.
Zacatecas
Yucatán
Veracruz de Ignacio de la Llave
Tlaxcala
Tamaulipas
Tabasco
Sonora
Sinaloa
San Luis Potosí
Quintana Roo
Querétaro
Puebla
Oaxaca
Nuevo León
Nayarit
México
Morelos
Michoacán de Ocampo
Mexico City
Jalisco
Hidalgo
Guerrero
Guanajuato
Durango
Colima
Coahuila
Chihuahua
Chiapas
Campeche
Baja California Sur
Baja California
Aguascalientes
Mar 20 May 20 Jul 20 Sep 20 Nov 20 Jan 21 Mar 21 May 21 Jul 21 Sep 21
Stress level
Low
Moderate
High
Extreme
All hospital beds
covid19.healthdata.org 24 Institute for Health Metrics and Evaluation
Mexico PROJECTIONS AND SCENARIOS
Figure 25. The estimated intensive care unit (ICU) usage is shown over time. The percent of ICU bedsoccupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion ofICU beds occupied by COVID-19 patients. Less than 10% is considered low stress, 10-29% is consideredmoderate stress, 30-59% is considered high stress, and 60% or greater is considered extreme stress.
Zacatecas
Yucatán
Veracruz de Ignacio de la Llave
Tlaxcala
Tamaulipas
Tabasco
Sonora
Sinaloa
San Luis Potosí
Quintana Roo
Querétaro
Puebla
Oaxaca
Nuevo León
Nayarit
México
Morelos
Michoacán de Ocampo
Mexico City
Jalisco
Hidalgo
Guerrero
Guanajuato
Durango
Colima
Coahuila
Chihuahua
Chiapas
Campeche
Baja California Sur
Baja California
Aguascalientes
Mar 20 May 20 Jul 20 Sep 20 Nov 20 Jan 21 Mar 21 May 21 Jul 21 Sep 21
Stress level
Low
Moderate
High
Extreme
Intensive care unit beds
covid19.healthdata.org 25 Institute for Health Metrics and Evaluation
Mexico MORE INFORMATION
More informationData sources:
Mask use and vaccine confidence data are from the Global COVID-19 Symptom Survey (this research isbased on survey results from University of Maryland Social Data Science Center with Facebook’s support)and the US COVID-19 Symptom Survey (this research is based on survey results from Carnegie MellonUniversity’s Delphi Research Group with Facebook’s support). Mask use data are also from Premise, theKaiser Family Foundation, and the YouGov COVID-19 Behaviour Tracker survey.
Genetic sequence and metadata are primarily from the GISAID Initiative. Further details available on theCOVID-19 model FAQ page.
A note of thanks:
We wish to warmly acknowledge the support of these and others who have made our COVID-19 estimationefforts possible.
More information:
For all COVID-19 resources at IHME, visit http://www.healthdata.org/covid.
Questions? Requests? Feedback? Please contact us at https://www.healthdata.org/covid/contact-us.
covid19.healthdata.org 26 Institute for Health Metrics and Evaluation